The fund comes only a few months after the startup was awarded a US patent for a novel AI-enabled image analysis technology
Healthcare startups in Egypt continue to expand as Egypt-based HealthTech startup Dileny Technologies (DilenyTech) LLC secures a $160,000 non-equity grant to expand AI-enable platform to improve and expedite breast cancer detection.
The fund comes only a few months after the startup was awarded a US patent for a novel AI-enabled image analysis technology.
DilenyTech received the fund from the Information Technology Academia Collaboration (ITAC) program affiliated with the Information Technology Industry Development Agency (ITIDA).
The second most common type of cancer, breast cancer records around 2 million new cases annually worldwide.
“DilenyTech aims to revolutionize breast cancer screening and diagnostic workflow via providing innovative AI assistance for more accurate breast cancer detection and expedited reporting. Thousands of healthcare professionals can access our online platform anytime/anywhere. This shall reduce patients’ suffering due to long waiting time as well as inaccurate diagnosis,” said Dr. Ahmed Ehab Mahmoud, Founder, and chief innovation officer.
DilenyTech provides solutions for medical imaging analysis, breast cancer risk assessment, and structured reporting in several medical applications to top-tier international health tech companies with active users in 3 different continents.
Found in 2018, the company already has +90 scientific publications and 3 US patents, with a combined team experience of more than 15 years.
DilenyTech has become one of the fast-growing Healthtech startups in Africa and the MENA regions specialized in AI and medical imaging analysis.
DilenyTech has been ranked the 2nd in the Decoding Health Challenge organized by Health 2.0 Egypt and UNESCO in Dec 2019 and is sponsored by Etisalat Misr and Novartis. DilenyTech was also chosen among the top 50 AI startups to watch in Africa 2020 according to Baobab Insights.
The HealthTech startup recently launched the first worldwide bi-lingual AI-enabled breast cancer risk assessment tool in Arabic and English. Also, the startup developed a vendor-neutral technology for urtlasound imaging that was awarded a US patent and validated throughout several studies.
